Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


U.S. FDA Approves Flublok®, the World's First Recombinant, Highly Purified, Egg-Free Influenza Vaccine

MERIDEN, Conn., Jan. 16, 2013 /PRNewswire/ -- 

  • The U.S. FDA approved Flublok for people 18-49 years old – making it the first recombinant vaccine for influenza available on the market. Approval for all people 18 years and above is expected later in 2013.
  • Flublok features:
    • First influenza vaccine made without the use of live influenza virus
    • First egg-free influenza vaccine
    • Highly purified without preservatives (thimerosal), antibiotics or adjuvants
    • Three times the active ingredient in traditional influenza vaccines
    • Manufactured in a fraction of the time required for traditional influenza vaccines

Protein Sciences Corporation announced today that the U.S. Food and Drug Administration (FDA) approved Flublok influenza vaccine for use in people 18-49 years old. 

Flublok is a novel protein vaccine for the prevention of seasonal influenza disease and is the first to be made in a 100% egg-free system without growing influenza viruses – so the vaccine can be made quickly and without any of the infectious risk traditionally associated with vaccine manufacture.  Flublok is highly purified, has three times the amount of active ingredient in traditional influenza vaccines, and contains no preservatives (thimerosal), antibiotics or adjuvants.

"Flublok is truly a modern vaccine," said Manon Cox, CEO of Protein Sciences.  She explained, "We use advanced scientific technology to make just the active ingredient of the vaccine without any other viral components.  This is the first influenza vaccine on the market to do so." 

Flublok and its sister vaccine, Panblok®, that is designed to protect against pandemic influenza, have been developed in partnership with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, through Contract No. HHS0100200900106C that was awarded in 2009.  Early clinical development of Flublok and Panblok was supported by generous grants from the National Institutes of Health through the Vaccine Treatment and Evaluation Units. 

Flublok will be widely available for the 2013-2014 influenza season and is available in limited supply for the current season.  Additional information about Flublok including patient information and announcements regarding where to get the vaccine can be found at www.flublok.com.  Please refer to the complete Flublok package insert available on the website for full prescribing information.

Flublok is a trivalent composition of recombinant influenza hemagglutinin (rHA) proteins that are manufactured using Protein Sciences' proprietary baculovirus expression vector system (BEVS) technology and expresSF+® cell line. 

About Us

Protein Sciences Corporation is a vaccine development and protein production company based in Meriden, CT that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceu­ticals. Our proprietary BEVS technology provides a fast, reliable and inexpensive platform for the production of high quality recombinant proteins, making it a powerful tool for producing vaccines and therapeutics when they are needed most.  BEVS technology is covered by broad patents that include our proprietary expresSF+® cell line that we use to make all of our products.

We recently expanded to Pearl River, NY where we will manufacture Flublok in addition to our Meriden, CT facility.

SOURCE Protein Sciences Corporation

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
For retailers everywhere, it’s a challenging new day. Security threats are a constant – both inside their four walls and out. The big security breaches we hear about on the news; the smaller ones sometimes not. But their impact remains costly to us all. The need for mobility, rapidly e...
I write and study often on the subject of digital transformation - the digital transformation of industries, markets, products, business models, etc. In brief, digital transformation is about the impact that collected and analyzed data can have when used to enhance business processes ...
I had the privilege of attending a mobile security event this week and speaking with many experts on the matter. I am not a mobile security expert, so my role was to speak on mobile strategies and trends and to learn as much as I could. What did I learn? I learned the difference b...
General Electric (GE) has been a household name for more than a century, thanks in large part to its role in making households easier to run. Starting with the light bulb invented by its founder, Thomas Edison, GE has been selling devices (“things”) to consumers throughout its 122-year...
It's time to condense all I've seen, heard, and learned about the IoT into a fun, easy-to-remember guide. Without further ado, here are Five (5) Things About the Internet of Things: 1. It's the end-state of Moore's Law. It's easy enough to debunk the IoT as “nothing new.” After all,...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE